RedHill Biopharma (RDHL) EPS (Basic): 2011-2024
Historic EPS (Basic) for RedHill Biopharma (RDHL) over the last 13 years, with Dec 2024 value amounting to -$0.00.
- RedHill Biopharma's EPS (Basic) rose 163.44% to $0.05 in Q2 2023 from the same period last year, while for Jun 2023 it was -$0.11, marking a year-over-year increase of 67.59%. This contributed to the annual value of -$0.00 for FY2024, which is 106.49% down from last year.
- RedHill Biopharma's EPS (Basic) amounted to -$0.00 in FY2024, which was down 106.49% from $0.01 recorded in FY2023.
- Over the past 5 years, RedHill Biopharma's EPS (Basic) peaked at $0.15 during FY2020, and registered a low of -$0.21 during FY2021.
- Its 3-year average for EPS (Basic) is -$0.04, with a median of -$0.00 in 2024.
- Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 243.91% in 2021, then skyrocketed by 108.33% in 2023.
- RedHill Biopharma's EPS (Basic) (Yearly) stood at $0.15 in 2020, then tumbled by 243.91% to -$0.21 in 2021, then skyrocketed by 42.56% to -$0.12 in 2022, then surged by 108.33% to $0.01 in 2023, then plummeted by 106.49% to -$0.00 in 2024.